Overview

A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in People With Celiac Disease

Status:
Not yet recruiting

Trial end date:
2025-04-02

Target enrollment:

Participant gender:

Summary

This study is to evaluate the Pharmacodynamic (PD), safety, tolerability, Pharmacokinetic (PK), and plasma biomarker response of KAN-101 in participants with Celiac Disease (CeD).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA